Managing Immune-Related Toxicities with Frontline RCC Therapies

A machine learning-based approach found that evaluating multiple biomarker features may identify outcomes and treatment resistance in renal cell carcinoma.

Manojkumar Bupathi, MD, MS, and Benjamin Garmezy, MD, highlight exciting trials in the genitourinary cancer space expected to be presented at 2025 ASCO.

Efficacy and safety outcomes in the phase 3 CONTACT-03 study were consistent regardless of patients' prior immunotherapy or tyrosine kinase inhibitor use.

Leaders in genitourinary oncology spoke about key research advances as well as personal experiences in navigating the field.

Data from the LITESPARK-015 trial supported the FDA’s decision to approve belzutifan monotherapy in patients with advanced, unresectable, or metastatic PPGL.

Data from the POTOMAC trial evaluating durvalumab in NMIBC will be presented at a future medical meeting and shared with global regulatory authorities.